DEWIZ
10.8.2021 11:51:08 CEST | Business Wire | Press release
deWiz’s Board of Directors, including co-founders Christian Bergh and Markus Westerberg, have announced Laszlo Varga as deWiz’s new Chief Executive Officer, starting August 16. Varga will apply his extensive experience leading e-commerce businesses like Gents and EuroFlorist to deWiz’s go-to-market strategy in golf and help develop strategic extensions for deWiz’s technology with other sports and disciplines. As CEO, Varga will oversee the start-up’s transition to a comprehensive global strategy by aligning all aspects of deWiz businesses using his expertise across consumer products, digital marketing, and direct sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005498/en/
Debuting this summer, deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback and high-precision swing data that accelerates golfers’ pace of learning and adds consistency. deWiz’s introduction to the golf and business world has already created a “buzz” with it being described by Forbes as looking to bring a “jolt to the golf training aid market ;” being profiled in Sweden’s leading financial media, Dagens Industri ; and being featured in Sport Techie’s Startups series .
“On behalf of my co-founder Markus and the deWiz board, I am thrilled to have Laszlo join our journey as we strive to help golfers improve faster with our science-backed technology as their competitive edge. As I continue as Chief Operations Officer for deWiz and as a board member, it’s a testament to how much we’ve accomplished since founding the company to have attracted somebody of Laszlo’s caliber and business acumen to lead our global strategy moving forward,” said Christian Bergh, co-founder and COO of deWiz.
“I’m super excited and proud to join the deWiz team. The product is truly revolutionary in helping athletes improve their performance by combining neural science with instant feedback and unmatched data capture. There is nothing else like deWiz in the golf market and the feedback we've gotten from the early users is overwhelmingly positive. With my experience and understanding of global e-commerce and direct sales to consumers, I hope to contribute to the accelerated growth and success of this awesome company that is on the front edge of innovation," said Laszlo Varga, CEO of deWiz.
Varga has a strong background in multi-national e-commerce and direct-to-consumer sales. Prior to joining deWiz, Laszlo was the CEO of Gents, a brand and online retailer for male grooming products. Before joining Gents, Varga was the CEO of Euroflorist, Europe’s largest flowers by wire company where he had a long and successful career, serving previously as Chief Operations Officer and Online Director, heading the online transition of sales. Varga’s entrepreneurial spirit and busines building skillset is also relied upon as a board member for Gents, CoolStuff and BoneProx. Varga is based in Malmö, Sweden, where he has spent the majority of his professional career after graduating from San Diego State University and competing at an elite level in kayaking.
DEVELOPED BY EXPERTS, TESTED BY PROS: deWiz’s has been in development for more than five years and has attracted an impressive roster of ambassadors, including 2020 U.S. Open Champion Bryson DeChambeau, 10-time Major Champion Annika Sorenstam, 3-time Major Champion Vijay Singh, 2-time Major Champion Lydia Ko, 2016 Open Champion Henrik Stenson, 2019 Houston Open Champion Lanto Griffin and 2-time World Long Drive Champion Tim Burke. deWiz’s user-friendly app and wearable tech tracks the precise position of a golfer’s hands throughout their swing, providing a 3D analysis and delivering data showcasing Transition , Length of Backswing , Wedge Distance and Tempo . These unique deWiz data points provide measurable metrics that any avid golfer, teaching professional or world-class player can utilize to efficiently refine their swing. Currently for sale for 699 USD, deWiz is available across the United States, Canada, Europe, and South Korea (more markets opening regularly – visit the website for the latest updates). Please visit dewizgolf.com for more details on how to improve your swing faster or download the app to demo its features via Apple’s App Store or Google Play.
ABOUT deWiz
The deWiz golf training platform has been developed by former European Tour pro, PGA of Sweden certified instructor and motor learning author, Markus Westerberg, and entrepreneur and technology business leader Christian Bergh. As a Swedish developed and produced product, deWiz is focused on its mission to help golfers around the world elevate their enjoyment of the game through innovative technology that accelerates the pace of learning. deWiz’s revolutionary wearable technology delivers groundbreaking instantaneous feedback that is based on a scientific approach of breaking cycles within motor learning and propelling golfers to improve faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom